Border between aplastic anemia and myelodysplastic syndrome

Area of Science:

• Hematology
• Oncology
• Pathophysiology

Background:

• Acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS) with low blast counts present diagnostic challenges due to overlapping morphological findings.
• Current diagnostic criteria may not fully capture the underlying pathophysiology of bone marrow (BM) failure, leading to misdiagnosis.
• Misdiagnosis can result in inappropriate and toxic treatments for patients with benign BM failure.

Observation:

• Morphological assessment alone is insufficient for differentiating AA from MDS.
• Biomarkers such as glycosylphosphatidylinositol-anchored protein-deficient cells and HLA-A lacking leukocytes can aid in distinguishing BM failure syndromes.
• Plasma thrombopoietin levels were identified as a highly useful marker.

Findings:

• Plasma thrombopoietin levels are a valuable tool for distinguishing between benign bone marrow failure syndromes (like AA) and pre-leukemic conditions (like MDS).
• This finding provides a more accurate method for classifying bone marrow failure.

Implications:

• Accurate differentiation of AA and MDS is crucial for appropriate patient management and treatment selection.
• Utilizing plasma thrombopoietin levels can prevent unnecessary and harmful therapies in patients with benign BM failure.
• Improved diagnostic strategies based on pathophysiology can lead to better patient outcomes in bone marrow failure syndromes.